Shlokka Dyes has approved a Rs 24.5 crore capital raise via equity shares and warrants, while reporting a jump in H1 revenue to Rs 71.62 crore. Investors must note auditor observations on profit-boosting accounting changes and deviations in IPO fund usage.
Shlokka Dyes Reports Strong H1 Results and Fundraising Plan
Revenue grew to Rs 71.62 crore from Rs 31.35 crore; Net profit surged to Rs 5.21 crore.
Reader Takeaway: Strong operational growth contrasts with auditor flags regarding accounting method changes and irregular IPO fund utilization.
What just happened
Shlokka Dyes Ltd has announced a board-approved fundraising plan of Rs 24.5 crore. The company intends to issue 39 lakh warrants and 31 lakh equity shares, all priced at Rs 35 each. To accommodate this expansion, the Board has proposed increasing the authorized share capital from Rs 22 crore to Rs 29 crore, pending shareholder approval at the EGM on November 28, 2026.
Why this matters
The capital raise aims to strengthen the balance sheet following a period of rapid growth. However, the filing includes significant auditor emphasis on matters that require investor caution. Notably, a change in depreciation methodology from WDV to SLM effectively boosted the half-year profit by Rs 0.90 crore, which is a non-operational increase in earnings.
Risks to watch
Auditors have raised concerns regarding the utilization of IPO proceeds. The company confirmed deviations where funds were diverted toward working capital and vendor payments not originally outlined in the IPO prospectus. Furthermore, the company acquired 'Equinox Impex'—a business owned by the Managing Director—for Rs 3.30 crore, a related-party transaction that warrants close scrutiny regarding valuation and business necessity.
Context metrics (H1 FY2026)
The company reported a robust performance for the six months ending September 30, 2026. Revenue stands at Rs 71.62 crore compared to Rs 31.35 crore in the previous year, while basic EPS rose to Rs 2.43 from Rs 0.98. Investors should consider how much of this growth is organic versus impacted by accounting adjustments and the acquisition of the MD's business undertaking.
What to track next
The EGM scheduled for November 28, 2026, will be the primary forum for shareholders to question management regarding the IPO fund deviations and the rationale behind the recent related-party acquisition.